Tesamorelin vs CJC-1295

At a glance

Evidence grade

Where a compliant provider sells this today

The short answer

These are not two strengths of one treatment. Both act on the growth-hormone-releasing hormone receptor, and there the similarity stops.

Tesamorelin was carried through controlled trials against a clinical outcome in a defined population, and it reached an FDA approval on that basis. The human work published under the CJC-1295 name measured hormone release in healthy adults, which is a pharmacology result rather than a benefit anyone would notice.

For the anti-aging and body-composition use both are actually sold on, neither has the evidence a buyer is being invited to assume. They arrive at that shortfall from opposite directions, and the difference is worth understanding before choosing between them.

One receptor, two different molecules

Growth-hormone-releasing hormone is made in the hypothalamus and tells the pituitary to release growth hormone. Both compounds are laboratory versions built to bind that receptor. Both leave the pituitary in charge, so the release they trigger still passes through the body’s own braking signals.

Tesamorelin is a stabilized analogue of the natural hormone. The modification exists to slow the enzymes that clear the natural signal within minutes.

CJC-1295 solves the same problem a different way, and only in one of its two forms. The long-acting version carries a drug affinity complex that binds it to a blood protein. The version most often sold does not carry that modification and is a shorter-acting molecule. Two products under one label are not therefore the same article.

What tesamorelin was actually tested for

Tesamorelin holds an FDA approval for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It got there the ordinary way, with controlled trials measuring a clinical outcome in the people the drug was meant to help.

The label is unusually direct about what the approval does not cover. It states that the product is not indicated for weight-loss management, and that long-term cardiovascular safety has not been established.

Both of those sentences are printed by the manufacturer, on the approved labeling, about the approved use. A wellness clinic selling tesamorelin for belly fat is selling outside the indication those trials described, and the label itself says where the edge of the evidence is.

What the CJC-1295 human file actually contains

The randomized human study indexed under this name asked a pharmacology question. It gave the long-acting version to healthy adults and measured growth hormone and insulin-like growth factor 1 in their blood.

That study answered its question. The molecule raised the hormone levels it was designed to raise, and the effect persisted longer than the natural signal would. Nothing in that design was meant to show whether a person slept better, recovered faster or looked different.

The gap between those two things is the entire subject of this comparison. A blood level moving is a measurement. It becomes evidence of benefit only once somebody demonstrates that moving it moves the outcome being sold.

The trial that would have settled it, and did not finish

CJC-1295 was once aimed at the same clinical question tesamorelin later won its approval for. A company-sponsored study of the compound in people with HIV and visceral obesity was registered and then terminated. The registry record shows no results and gives no reason.

A stopped trial is not a finding. It does not show the compound failed, and reading it that way would be as wrong as reading it as a success.

What it does show is that the question was asked and never answered on the public record. The clearest comparison anyone could have drawn between these two molecules is the one that does not exist.

Why both carry the same grade despite the approval

Both sit in the limited tier here, and the reasons are different. This site grades the use a compound is actually sold for in this market, which for both of these is longevity, body composition and general wellness.

For tesamorelin, the approved indication rests on its own controlled trial base and would be read very differently. Grading the label would tell a wellness buyer something true about a population they are not in.

For CJC-1295, the limited grade is earned by mechanism rather than by outcomes. The growth hormone axis genuinely responds, and that response has been measured in people. The long-term human outcome data the consumer claims would require has not been published.

Where the regulatory question sits

Tesamorelin holds an approval, and whether and how it may be compounded is a separate question that is unsettled. CJC-1295 has no FDA-approved product behind it in any indication, and which substances may lawfully be compounded is likewise unsettled.

No outcome, timeline or likelihood is characterized here. Positions like these move on their own schedule, and each compound carries a dated status record on this site where the current position is stated.

The practically useful part is what compounded means. A compounded preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, whatever an individual pharmacy’s own standards are. That describes the review pathway, not any particular pharmacy.

What would change either grade

The same thing for both, and tesamorelin has already shown it is reachable for this class of molecule. Randomized, placebo-controlled trials in adults resembling the people who buy the product, measuring outcomes those adults would notice, running long enough to show the effect persists.

For CJC-1295 there is an extra condition. The published human work was done on the long-acting version, and the version commonly sold is a different molecule. Evidence generated on one would need to be generated again on the other, or the vial would need to match the study.

Neither grade moves on a mechanism, a marker or a longer duration of action. Those are reasons to run the trial, not substitutes for having run it.